<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450578</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_DSM265_14_01</org_study_id>
    <nct_id>NCT02450578</nct_id>
  </id_info>
  <brief_title>DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria</brief_title>
  <official_title>Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy of DSM265 as a causal prophylactic in a standardized and&#xD;
      validated Human Challenge model using direct venous inoculation of aseptic, purified,&#xD;
      cryopreserved, vialed Plasmodium falciparum sporozoites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study follows the First In Human dose-escalation study of DSM265 (25 - 800 mg of DSM265)&#xD;
      and an Induced-Blood Stage Malaria Challenge study (150 mg of DSM265) conducted in healthy&#xD;
      adult volunteers in Australia. After identification of efficacious DSM265 plasma&#xD;
      concentrations in the Induced-Blood Stage Malaria model, the current study will evaluate the&#xD;
      efficacy of DSM265 as a causal prophylactic in a standardized and validated Human Challenge&#xD;
      model using direct venous inoculation of aseptic, purified, cryopreserved, vialed Plasmodium&#xD;
      falciparum sporozoites (Challenge).&#xD;
&#xD;
      Three sequential cohorts of healthy male and women volunteers, of non-childbearing potential&#xD;
      or of childbearing potential with predefined accepted methods of contraception, are planned&#xD;
      in order to investigate three preventive conditions with regard to administration of DSM265.&#xD;
      Preventive administration of the study drug will occur 1 and 7 days before inoculum of&#xD;
      Plasmodium falciparum sporozoite Challenge, with a last cohort administered at a time point&#xD;
      to be determined from the 2 previous cohorts but which will not exceed 28 days before the&#xD;
      challenge. The study will also include a cohort where subjects will be treated with&#xD;
      atovaquone-proguanil (Malarone®) using the approved regimen for chemoprophylaxis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection Rate</measure>
    <time_frame>Day 0 to Day 28 post-inoculum (daily)</time_frame>
    <description>The infection rate is the number (percentage) of subjects in a cohort who became positive for parasitemia.&#xD;
Complete protection = Subjects with pre-patent period equal to 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-patent Period</measure>
    <time_frame>Day 0 to Day 28 post-inoculum (daily)</time_frame>
    <description>The pre-patent period is defined as the time (days) from inoculation with PfSPZ to first occurrence of a positive TBS. If no positive TBS is seen by Day 28, this variable is set to 28 days.&#xD;
Complete protection = Subjects showing with pre-patent period equal to 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety &amp; Tolerability of DSM265</measure>
    <time_frame>From first dose (Day -1 in Cohort 1A and Day -7 in Cohort 2) to Day 60 post-inoculum</time_frame>
    <description>Safety &amp; tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a non-immune healthy volunteers in CHMI with PfSPZ challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety &amp; Tolerability of Malarone</measure>
    <time_frame>From first dose (Day -1, Cohort 1b) to Day 60 post-inoculum</time_frame>
    <description>Safety &amp; tolerability of Malarone for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a Plasmodium falciparum sporozoite challenge. Measured by adverse events, laboratory data.&#xD;
Malarone® was administered as a single daily dose over a period of 9 days from Day -1 to Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum</measure>
    <time_frame>Day 0 to Day 60 post-inoculum</time_frame>
    <description>Safety &amp; tolerability of Plasmodium falciparum sporozoite challenge inoculum during DSM265 administration, and Malarone administration. Measured by adverse events, laboratory data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - T Max</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - T 1/2</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - C Max</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-∞, AUC 0-168h, and AUC 0-480h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - CL/F</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM265 Pharmacokinetics Profile - Vz/F</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM450 Pharmacokinetics Profile - T Max</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM450 Pharmacokinetics Profile - Cmax</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h</measure>
    <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
    <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-t, AUC 0-168h, and AUC 0-480h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetic-pharmacodynamic Profile of Pre-administration of DSM265 on Clearance of Plasmodium Falciparum Parasites After Administration of the Sporozoite Challenge</measure>
    <time_frame>From first dose of DSM265 (Day -1 in Cohort 1a, Day -7 in Cohort 2 and Day -X in Cohort 3) to 480 hours post-dose</time_frame>
    <description>The profile of plasma concentrations and pharmacokinetic parameters (AUC, Cmax, Tmax, T0-inf, AUC0-t, t1/2) will be reviewed on a background of the safety profile (adverse events, laboratory and ECG data) and the clearance of Plasmodium falciparum parasites (efficacy) after administration of the sporozoite challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recrudescence of Parasite Kinetics Following DSM265 Administration.</measure>
    <time_frame>Day 6 post-inoculum to Day 60</time_frame>
    <description>On any re-appearance of parasites, thick smears and PCR samples will be examined to determine whether the parasite is a different variant(recrudescence) or has the same genetic profile as the original infection (re-infection) post-dose</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Plasmodium Falciparum, Malaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1a: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b: Malarone, sporozoite inoculum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSM265 400mg</intervention_name>
    <description>DSM265 400mg, single oral administration in a fed state</description>
    <arm_group_label>Cohort 1a: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 2: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to DSM265 400 mg</intervention_name>
    <description>Placebo to DSM265 400mg, single oral administration in a fed state</description>
    <arm_group_label>Cohort 1a: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 2: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum sporozoite challenge</intervention_name>
    <description>IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
    <arm_group_label>Cohort 1a: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 1b: Malarone, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 2: DSM265/placebo, sporozoite inoculum</arm_group_label>
    <arm_group_label>Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)</arm_group_label>
    <other_name>Sporozoite inoculum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Malarone</intervention_name>
    <description>250 mg atovaquone, 100 mg proguanil hydrochloride</description>
    <arm_group_label>Cohort 1b: Malarone, sporozoite inoculum</arm_group_label>
    <other_name>atovaquone / proguanil hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good health based on medical history and physical examination- Body mass index &gt;18 and&#xD;
             &lt;30 kg/m2&#xD;
&#xD;
          -  Lab results without clinically significant findings in 28 days prior to enrolment&#xD;
&#xD;
          -  Negative drug screening test&#xD;
&#xD;
          -  Females: negative pregnancy test at screening and on the day before first dose of&#xD;
             DSM265 and sporozoite challenge injection&#xD;
&#xD;
          -  Sexually active males must agree to use a medically acceptable form of contraception&#xD;
             from enrolment and continue for 12 weeks after the dose of DSM265&#xD;
&#xD;
          -  Women may only be included if they are either Identified as not of child bearing&#xD;
             potential, or if of child bearing potential and willing and able to practice one of&#xD;
             the continuous acceptable methods of contraception (must be one with failure rate less&#xD;
             than 1% per year) with double barrier protection:&#xD;
&#xD;
               -  Intrauterine device+condoms,&#xD;
&#xD;
               -  Diaphragms+spermicidal gel/foam+condoms,&#xD;
&#xD;
               -  Hormonal contraceptives (oral, depot, patch, injectable or vaginal ring)&#xD;
                  stabilized for at least 30 days before the study drug + condoms from screening to&#xD;
                  at least 60 days after dose of DSM265&#xD;
&#xD;
          -  Agree to allow the investigators to discuss the medical history with General&#xD;
             Practitioner and to sign a request to release medical information concerning&#xD;
             contra-indications for participation in the study&#xD;
&#xD;
          -  Able and willing to comply with all study requirements for the duration of the study&#xD;
&#xD;
          -  Agree to undergo all study procedures, to attend all study visits and stay overnight&#xD;
             for observation if required, up to last follow up visit&#xD;
&#xD;
          -  Willing to undergo a sporozoite challenge&#xD;
&#xD;
          -  Able and willing to answer all questions on the informed consent quiz correctly&#xD;
             demonstrating an understanding of the meaning and of the study procedures&#xD;
&#xD;
          -  Able and willing to sign the informed consent form&#xD;
&#xD;
          -  Reachable (24/7) by mobile phone or email during the whole study period&#xD;
&#xD;
          -  Agree to refrain from blood donation during the course of the study and after the end&#xD;
             of involvement in the study according to the local and national blood banking&#xD;
             eligibility criteria (currently 4 years in Germany)&#xD;
&#xD;
          -  Willing to take a curative regimen of Riamet or another registered antimalarial if&#xD;
             necessary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of malaria&#xD;
&#xD;
          -  Plans to travel to malaria endemic region during the study period up to last follow up&#xD;
             visit or plans to travel outside of Germany during the challenge period&#xD;
&#xD;
          -  unable to be closely followed for social, geographic or psychological reasons&#xD;
&#xD;
          -  Previous participation in any malaria vaccine study or controlled human malaria&#xD;
             infection study&#xD;
&#xD;
          -  Participation in any other clinical study within 30 days before enrolment in the&#xD;
             study, or plan to participate in another investigational vaccine/drug research during&#xD;
             the study period.&#xD;
&#xD;
          -  Woman who is breast-feeding or planning to become pregnant during the study&#xD;
&#xD;
          -  Positive human immunodeficiency virus, seropositive for hepatitis B surface antigen or&#xD;
             Hepatitis C virus tests&#xD;
&#xD;
          -  Any confirmed/suspected immunosuppressive or immunodeficient state, including human&#xD;
             immunodeficiency virus infection, asplenia, recurrent, severe infections and chronic&#xD;
             (more than 14 days) immunosuppressant medication within the 6 months before enrolment&#xD;
             (inhaled and topical steroids are allowed)&#xD;
&#xD;
          -  History of serious psychiatric condition that may affect participation in the study,&#xD;
             precludes compliance with the protocol; past or present psychoses; disorder requiring&#xD;
             lithium; or within 5 years prior to enrolment, history of a suicide plan or attempt.&#xD;
&#xD;
          -  History of convulsions or severe head trauma&#xD;
&#xD;
          -  Symptoms, physical signs and lab values suggestive of systemic disorders including&#xD;
             renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, and other&#xD;
             conditions which could interfere with the interpretation of the study results or&#xD;
             compromise health&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin), or diabetes mellitus or&#xD;
             of arrhythmias or documented prolonged QTF-interval (&gt;450msec)&#xD;
&#xD;
          -  Clinically significant abnormalities in electrocardiogram at screening: pathologic Q&#xD;
             wave, prolonged QT interval, and significant ST-T wave changes, left ventricular&#xD;
             hypertrophy, non-sinus rhythm except isolated premature atrial contractions, right or&#xD;
             left bundle branch block, advanced A-V heart block (type 2 or type 3)&#xD;
&#xD;
          -  In moderate risk or higher categories for fatal or non-fatal cardiovascular event&#xD;
             within 5 years (&gt;10%) determined by non-invasive criteria for cardiac risk&#xD;
&#xD;
          -  Positive family history in relatives &lt;50 years for cardiac disease&#xD;
&#xD;
          -  History of psoriasis or porphyria, which may be exacerbated by chloroquine&#xD;
&#xD;
          -  History of splenectomy&#xD;
&#xD;
          -  Sickle cell anaemia or other red blood cell disorders&#xD;
&#xD;
          -  History of allergy or contra-indications to or having contraindications to the use of&#xD;
             chloroquine phosphate, atovaquone-proguanil (cohort 1B), artemether or lumefantrine&#xD;
&#xD;
          -  Use of any prescription drugs (except contraception), herbal supplements or&#xD;
             over-the-counter medication in 4 weeks before dosing or 5x half-lives, whichever is&#xD;
             longer&#xD;
&#xD;
          -  Use or anticipated use of medications known to cause drug reactions with rescue&#xD;
             medications or Malarone, such as cimetidine, metoclopramide, antacids and taken at any&#xD;
             point during the study period.&#xD;
&#xD;
          -  Intake of grapefruit, grapefruit juice, Seville orange or other products containing&#xD;
             these ingredients within 7 days of the first drug administration&#xD;
&#xD;
          -  Use of chronic immunosuppressive drugs, or other immune modifying drugs within 6&#xD;
             months of enrolment (inhaled and topical corticosteroids and oral anti-histaminic are&#xD;
             allowed) and/or during the study period&#xD;
&#xD;
          -  Use of systemic antibiotics with known antimalarial activity within 30 days of study&#xD;
             enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,&#xD;
             erythromycin, fluoroquinolones, or azithromycin ) and/or during the study period&#xD;
&#xD;
          -  Use of immunoglobulins or blood products in 3 months prior to enrolment&#xD;
&#xD;
          -  Suspected/known injecting drug abuse in 5 years preceding enrolment&#xD;
&#xD;
          -  Current smoking more than 10 cigarettes or equivalent per day&#xD;
&#xD;
          -  Plan for major surgery between enrolment and follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Mordmüller, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Tropenmedizin, Uni. of Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Institut für Tropenmedizin</name>
      <address>
        <city>Tübingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Sulyok M, Rückle T, Roth A, Mürbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibáñez J, Sulyok Z, Held J, Gebru T, Granados P, Brückner S, Nguetse C, Mengue J, Lalremruata A, Sim BKL, Hoffman SL, Möhrle JJ, Kremsner PG, Mordmüller B. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017 Jun;17(6):636-644. doi: 10.1016/S1473-3099(17)30139-1. Epub 2017 Mar 28. Erratum in: Lancet Infect Dis. 2017 Jun;17(6):576.</citation>
    <PMID>28363637</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <results_first_submitted>July 22, 2019</results_first_submitted>
  <results_first_submitted_qc>November 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria, Plasmodium falciparum sporozoite challenge, DSM265</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 40 subjects were screened. Of these 22 (55.0%) were enrolled to participate in the study</recruitment_details>
      <pre_assignment_details>One subject was allocated to treatment but did not receive any study medication due to an ECG abnormality discovered after randomization and, therefore, 21 out of 22 subjects received at least one dose of the study medications.&#xD;
In agreement with the Safety Review Team, the Sponsor decided to close the study without progressing to conduct Cohort 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1A: 400 mg DSM265, Sporozoite Challenge</title>
          <description>DSM265 400mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
          <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: 400 mg DSM265, Sporozoite Challenge</title>
          <description>DSM265 400mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="P4">
          <title>Placebo Cohorts 1A and 2, Sporozoite Challenge</title>
          <description>Placebo to DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
Placebo: Single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ECG abnormality so not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>one subject in cohort 1A was excluded prior to dosing</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1A: 400 mg DSM265, Sporozoite Challenge</title>
          <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
          <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: 400 mg DSM265, Sporozoite Challenge</title>
          <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="B4">
          <title>Placebo Cohorts 1A and 2</title>
          <description>Placebo to DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
Placebo to DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.20" spread="4.02"/>
                    <measurement group_id="B2" value="26.67" spread="4.93"/>
                    <measurement group_id="B3" value="25.33" spread="4.18"/>
                    <measurement group_id="B4" value="24.82" spread="3.95"/>
                    <measurement group_id="B5" value="26.00" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infection Rate</title>
        <description>The infection rate is the number (percentage) of subjects in a cohort who became positive for parasitemia.&#xD;
Complete protection = Subjects with pre-patent period equal to 28 days.</description>
        <time_frame>Day 0 to Day 28 post-inoculum (daily)</time_frame>
        <population>All subjects who received both at least one dose of study medication and the PfSPZ challenge</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
            <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohorts 1A and 2</title>
            <description>Placebo to DSM265 400 mg on Day -7 or Day -1, sporozoite challenge on Day 0&#xD;
Placebo to DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Rate</title>
          <description>The infection rate is the number (percentage) of subjects in a cohort who became positive for parasitemia.&#xD;
Complete protection = Subjects with pre-patent period equal to 28 days.</description>
          <population>All subjects who received both at least one dose of study medication and the PfSPZ challenge</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Protection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parasitemic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre-patent Period</title>
        <description>The pre-patent period is defined as the time (days) from inoculation with PfSPZ to first occurrence of a positive TBS. If no positive TBS is seen by Day 28, this variable is set to 28 days.&#xD;
Complete protection = Subjects showing with pre-patent period equal to 28 days.</description>
        <time_frame>Day 0 to Day 28 post-inoculum (daily)</time_frame>
        <population>All subjects who received both at least one dose of study medication and the PfSPZ challenge</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
            <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohorts 1A and 2</title>
            <description>Placebo to DSM265 400 mg on Day -7 or Day -1, sporozoite challenge on Day 0&#xD;
Placebo to DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-patent Period</title>
          <description>The pre-patent period is defined as the time (days) from inoculation with PfSPZ to first occurrence of a positive TBS. If no positive TBS is seen by Day 28, this variable is set to 28 days.&#xD;
Complete protection = Subjects showing with pre-patent period equal to 28 days.</description>
          <population>All subjects who received both at least one dose of study medication and the PfSPZ challenge</population>
          <units>Days</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="0.00"/>
                    <measurement group_id="O2" value="28.0" spread="0.00"/>
                    <measurement group_id="O3" value="20.6" spread="2.78"/>
                    <measurement group_id="O4" value="11.7" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety &amp; Tolerability of DSM265</title>
        <description>Safety &amp; tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a non-immune healthy volunteers in CHMI with PfSPZ challenge.</description>
        <time_frame>From first dose (Day -1 in Cohort 1A and Day -7 in Cohort 2) to Day 60 post-inoculum</time_frame>
        <population>All the subjects included in the safety population were administered the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a: DSM265/Placebo, Sporozoite Inoculum</title>
            <description>DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0&#xD;
DSM265 400mg: DSM265 400mg, single oral administration in a fed state&#xD;
Placebo to DSM265 400 mg: Placebo to DSM265 400mg, single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: DSM265/Placebo, Sporozoite Inoculum</title>
            <description>DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0&#xD;
DSM265 400mg: DSM265 400mg, single oral administration in a fed state&#xD;
Placebo to DSM265 400 mg: Placebo to DSM265 400mg, single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety &amp; Tolerability of DSM265</title>
          <description>Safety &amp; tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a non-immune healthy volunteers in CHMI with PfSPZ challenge.</description>
          <population>All the subjects included in the safety population were administered the study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety &amp; Tolerability of Malarone</title>
        <description>Safety &amp; tolerability of Malarone for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a Plasmodium falciparum sporozoite challenge. Measured by adverse events, laboratory data.&#xD;
Malarone® was administered as a single daily dose over a period of 9 days from Day -1 to Day 7.</description>
        <time_frame>From first dose (Day -1, Cohort 1b) to Day 60 post-inoculum</time_frame>
        <population>All the subjects included in the safety population were administered the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
            <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety &amp; Tolerability of Malarone</title>
          <description>Safety &amp; tolerability of Malarone for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a Plasmodium falciparum sporozoite challenge. Measured by adverse events, laboratory data.&#xD;
Malarone® was administered as a single daily dose over a period of 9 days from Day -1 to Day 7.</description>
          <population>All the subjects included in the safety population were administered the study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum</title>
        <description>Safety &amp; tolerability of Plasmodium falciparum sporozoite challenge inoculum during DSM265 administration, and Malarone administration. Measured by adverse events, laboratory data</description>
        <time_frame>Day 0 to Day 60 post-inoculum</time_frame>
        <population>All the subjects included in the safety population were administered the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
            <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O4">
            <title>Placebo Cohorts 1A and 2</title>
            <description>Placebo to DSM265 400 mg on Day -7 or Day -1, sporozoite challenge on Day 0&#xD;
Placebo to DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum</title>
          <description>Safety &amp; tolerability of Plasmodium falciparum sporozoite challenge inoculum during DSM265 administration, and Malarone administration. Measured by adverse events, laboratory data</description>
          <population>All the subjects included in the safety population were administered the study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - T Max</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - T Max</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T max DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.00" upper_limit="14.0"/>
                    <measurement group_id="O2" value="8.48" lower_limit="0.500" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T max Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.02"/>
                    <measurement group_id="O2" value="8.48" lower_limit="0.500" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - T 1/2</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - T 1/2</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t 1/2 DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" spread="31.4"/>
                    <measurement group_id="O2" value="113" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t 1/2 Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="34.8"/>
                    <measurement group_id="O2" value="116" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - C Max</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - C Max</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C max DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6860" spread="28.2"/>
                    <measurement group_id="O2" value="6990" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C max Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13300" spread="34.3"/>
                    <measurement group_id="O2" value="11200" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h</title>
        <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-∞, AUC 0-168h, and AUC 0-480h</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h</title>
          <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-∞, AUC 0-168h, and AUC 0-480h</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-∞ DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="979000" spread="25.8"/>
                    <measurement group_id="O2" value="906000" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-∞ Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1870000" spread="23.4"/>
                    <measurement group_id="O2" value="1540000" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-168h DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582000" spread="22.8"/>
                    <measurement group_id="O2" value="568000" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-168h Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100000" spread="22.3"/>
                    <measurement group_id="O2" value="949000" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-480h DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="863000" spread="22.0"/>
                    <measurement group_id="O2" value="847000" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-480h Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1680000" spread="19.5"/>
                    <measurement group_id="O2" value="1430000" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - CL/F</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - CL/F</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL/F DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409" spread="25.8"/>
                    <measurement group_id="O2" value="441" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL/F Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" spread="23.4"/>
                    <measurement group_id="O2" value="260" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM265 Pharmacokinetics Profile - Vz/F</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM265 Pharmacokinetics Profile - Vz/F</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vz/F DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77900" spread="29.0"/>
                    <measurement group_id="O2" value="71700" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vz/F Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41400" spread="31.8"/>
                    <measurement group_id="O2" value="43600" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM450 Pharmacokinetics Profile - T Max</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM450 Pharmacokinetics Profile - T Max</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t max DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="71.9" upper_limit="265"/>
                    <measurement group_id="O2" value="216" lower_limit="48.3" upper_limit="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t max Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="71.9" upper_limit="265"/>
                    <measurement group_id="O2" value="169" lower_limit="72.4" upper_limit="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM450 Pharmacokinetics Profile - Cmax</title>
        <description>Pre-dose and post-dose during the period including Day 28</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM450 Pharmacokinetics Profile - Cmax</title>
          <description>Pre-dose and post-dose during the period including Day 28</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545" spread="35.3"/>
                    <measurement group_id="O2" value="714" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999" spread="31.0"/>
                    <measurement group_id="O2" value="1170" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h</title>
        <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-t, AUC 0-168h, and AUC 0-480h</description>
        <time_frame>From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum</time_frame>
        <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h</title>
          <description>Pre-dose and post-dose during the period including Day 28 for AUC 0-t, AUC 0-168h, and AUC 0-480h</description>
          <population>All subjects who received study drug and provided they had sufficient DSM265 and/or DSM450 concentration data for the non-compartmental analysis were included in the pharmacokinetic analysis (all-treated set).</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-∞ DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185000" spread="34.9"/>
                    <measurement group_id="O2" value="225000" spread="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-∞ Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326000" spread="32.1"/>
                    <measurement group_id="O2" value="367000" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-168h DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63800" spread="44.9"/>
                    <measurement group_id="O2" value="85300" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-168h Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115000" spread="45.9"/>
                    <measurement group_id="O2" value="142000" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-480h DBS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185000" spread="34.9"/>
                    <measurement group_id="O2" value="234000" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-480h Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326000" spread="32.1"/>
                    <measurement group_id="O2" value="375000" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetic-pharmacodynamic Profile of Pre-administration of DSM265 on Clearance of Plasmodium Falciparum Parasites After Administration of the Sporozoite Challenge</title>
        <description>The profile of plasma concentrations and pharmacokinetic parameters (AUC, Cmax, Tmax, T0-inf, AUC0-t, t1/2) will be reviewed on a background of the safety profile (adverse events, laboratory and ECG data) and the clearance of Plasmodium falciparum parasites (efficacy) after administration of the sporozoite challenge</description>
        <time_frame>From first dose of DSM265 (Day -1 in Cohort 1a, Day -7 in Cohort 2 and Day -X in Cohort 3) to 480 hours post-dose</time_frame>
        <population>Data were not collected. Analysis was not done because, because all subjects were administered with the same dose of 400mg DSM; so not enough variability for the &quot;DSM concentration&quot; parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetic-pharmacodynamic Profile of Pre-administration of DSM265 on Clearance of Plasmodium Falciparum Parasites After Administration of the Sporozoite Challenge</title>
          <description>The profile of plasma concentrations and pharmacokinetic parameters (AUC, Cmax, Tmax, T0-inf, AUC0-t, t1/2) will be reviewed on a background of the safety profile (adverse events, laboratory and ECG data) and the clearance of Plasmodium falciparum parasites (efficacy) after administration of the sporozoite challenge</description>
          <population>Data were not collected. Analysis was not done because, because all subjects were administered with the same dose of 400mg DSM; so not enough variability for the &quot;DSM concentration&quot; parameter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recrudescence of Parasite Kinetics Following DSM265 Administration.</title>
        <description>On any re-appearance of parasites, thick smears and PCR samples will be examined to determine whether the parasite is a different variant(recrudescence) or has the same genetic profile as the original infection (re-infection) post-dose</description>
        <time_frame>Day 6 post-inoculum to Day 60</time_frame>
        <population>Recrudescence was not observed in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
            <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
          </group>
        </group_list>
        <measure>
          <title>Recrudescence of Parasite Kinetics Following DSM265 Administration.</title>
          <description>On any re-appearance of parasites, thick smears and PCR samples will be examined to determine whether the parasite is a different variant(recrudescence) or has the same genetic profile as the original infection (re-infection) post-dose</description>
          <population>Recrudescence was not observed in this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the day of dosing until Day 60 following PfSPZ challenge: Cohort 1A: 61 days Cohort 1B (Malarone): 61 days Cohort 2: 68 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)</title>
          <description>DSM265 400 mg on Day -1, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1B: Malarone, Sporozoite Challenge</title>
          <description>Malarone daily for 9 days from Day -1 to Day 7, sporozoite challenge Day 0&#xD;
Malarone: 250 mg atovaquone, 100 mg proguanil hydrochloride&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)</title>
          <description>DSM265 400 mg on Day -7, sporozoite challenge on Day 0&#xD;
DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
        <group group_id="E4">
          <title>Placebo Cohorts 1A and 2</title>
          <description>Placebo to DSM265 400 mg on Day -7 or Day -1, sporozoite challenge on Day 0&#xD;
Placebo to DSM265 400 mg: single oral administration in a fed state&#xD;
Plasmodium falciparum sporozoite challenge: Plasmodium falciparum sporozoites (3200) by direct venous inoculation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>One SAE was reported (pulmonary embolism) which was considered to be unrelated to the study drug due to identified risk factors (oral contraception, transatlantic flight) and timing of event (34 days after treatment intake).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="11" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jörg Möhrle</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0330</phone>
      <email>moehrlej@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

